Prognostic Sub-Grouping of Diffuse Large B-Cell Lymphomas into Germinal Centre And Post Germinal Centre Groups by Immunohistochemistry after 6 Cycles of Chemotherapy |
Hassan, Usman
(Department of Histopathology, Armed Forces Institute of Pathology)
Mushtaq, Sajid (Department of Histopathology, Armed Forces Institute of Pathology) Mamoon, Nadira (Department of Histopathology, Armed Forces Institute of Pathology) Asghar, Asghar Hussain (Department of Histopathology, Armed Forces Institute of Pathology) Ishtiaq, Sheeba (Department of Histopathology, Armed Forces Institute of Pathology) |
1 | Abbasi AN, Zahid S, Karsan F, Ali N, Bhurgri Y (2010). Lymphoma cases referred to the radiation oncology service of a tertiary referral university hospital in Karachi, Pakistan: a retrospective study. Asian Pac J Cancer Prev, 11, 107-10. |
2 | Aftab K, Bhurgri Y, Pervez S (2006). Small B cell Non-Hodgkins Lymphoma in Pakistan. J Pak Med Assoc, 56, 22-5. |
3 | Borovecki A, Korac P, Nola M, Ivankovic D, Jaksic B, Dominis M (2008). Prognostic significance of B-cell differentiation genes encoding proteins in diffuse large B-cell lymphoma and follicular lymphoma grade 3. Croat Med J, 49, 625-35. DOI |
4 | Cheson BD (2008). New staging and response criteria for non- Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am, 46, 213-23. DOI |
5 | Cheson BD, Pfistner B, Juweid ME, et al (2007). Revised response criteria for malignant lymphoma. J Clin Oncol, 25, 579-86. DOI ScienceOn |
6 | Choi WW, Weisenburger DD, Greiner TC, et al (2009). A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. Clin Cancer Res, 15, 5494-502. DOI |
7 | De Jong D, Xie W, Rosenwald A, et al (2009). Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium). J Clin Pathol, 62, 128-38. DOI |
8 | Fu K, Weisenburger DD, Choi WW, et al (2008). Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol, 26, 4587-94. DOI |
9 | Haarer CF, Roberts RA, Frutiger YM, Grogan TM, Rimsza LM (2006). Immunohistochemical classification of de Novo, transformed, and relapsed diffuse large B-Cell lymphoma into germinal center B-Cell and nongerminal center B-Cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med, 130, 1819-24. |
10 | Ilic I, Mitrovic Z, Aurer I, et al (2009). Lack of prognostic significance of the germinal-center phenotype in diffuse large B-cell lymphoma patients treated with CHOP-like chemotherapy with and without rituximab. Int J Hematol, 90, 74-80. DOI |
11 | Jaffe ES, Harris NL, Stein H, Isaacson PG (2008). Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood, 112, 4384-99. DOI |
12 | Jamal S, Moghal S, Mamoon N, (2006). The pattern of malignant tumours: tumour registry data analysis, AFIP, Rawalpindi, Pakistan (1992-2001). J Pak Med Assoc, 56, 359-62. |
13 | Karin ES (2006). Epidemiology and etiology of non-Hodgkin lymphoma - a review. Acta Oncologica, 45, 258-271. DOI |
14 | Lossos IS, Morgensztern D (2006). Prognostic biomarkers in diffuse large B-cell lymphoma. J Clin Oncol, 24, 995-1007. DOI |
15 | Malumbres R, Chen J, Tibshirani R, et al (2008). Paraffinbased 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood, 111, 5509-14. DOI |
16 | Muris JJ, Meijer CJ, Vos W, et al (2006). Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 208, 714-23. DOI |
17 | Mushtaq S, Akhtar N, Jamal S, et al (2008). Malignant lymphomas in Pakistan according to the WHO classification of lymphoid neoplasms. Asian Pac J Cancer Prev, 9, 229-32. |
18 | Oh YH, Park CK (2006). Prognostic evaluation of nodal diffuse large B cell lymphoma by immunohistochemical profiles with emphasis on CD138 expression as a poor prognostic factor. J Korean Med Sci, 21, 397-405. DOI |
19 | Saad AA, Awed NM, Abdel-Hafeez ZM, et al (2010). Prognostic value of immunohistochemical classification of diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes. Saudi Med J, 31, 135-41. |
20 | Rimsza LM, Leblanc ML, Unger JM, et al (2008). Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 112, 3425-33. DOI |
21 | Sehn LH, Berry B, Chhanabhai M, et al (2007). The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood, 109, 1857-61. DOI |
22 | Seki R, Ohshima K, Fujisaki T, et al (2009). Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci, 100, 1842-7. DOI |
23 | Sjo LD, Poulsen CB, Hansen M, Moller MB, Ralfkiaer E (2007). Profiling of diffuse large B-cell lymphoma by immunohistochemistry: identification of prognostic subgroups. Eur J Haematol, 79, 501-7. DOI ScienceOn |
24 | Veelken H, Vik Dannheim S, Schulte Moenting J, et al (2007). Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy. Ann Oncol, 18, 931-9. DOI |
25 | Wagner SD, Amen F, Trivedi PS, et al (2007). Bcl-6 and c-Myc are rarely co-expressed in adult diffuse large B-cell lymphoma. Leuk Lymphoma, 48, 1510-3. DOI |
26 | Winter JN, Weller EA, Horning SJ, et al (2006). Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood, 107, 4207-13. DOI |
27 | Zaja F, Tomadini V, Zaccaria A, et al (2006). CHOP-rituximab with pegylated liposomal doxorubicin for the treatment of elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma, 47, 2174-80. DOI |
28 | Xu JZ, Guo Z, Zhang M, Li X, Li YJ, Rao SQ (2006). Peeling off the hidden genetic heterogeneities of cancers based on disease-relevant functional modules. Mol Med, 12, 25-33. |